Ultragenyx snares FDA nod for ultraorphan med Mepsevii, and a valuable voucher, too
admin 15th November 2017 Uncategorised 0Rare disease biotech Ultragenyx has won its first FDA approval with Mepsevii, an enzyme replacement therapy expected to carry a high price to treat a tiny group of patients. And with that approval, Ultragenyx also snared a priority review voucher potentially worth hundreds of millions.
More: Ultragenyx snares FDA nod for ultraorphan med Mepsevii, and a valuable voucher, too
Source: fierce